Jun,2023. Retagliptin Phosphate Tablets, the Class 1. New drug from Jiangsu Hengrui Pharmaceuticals Co., Ltd for the treatment of type 2 diabetes, is approved by China NMPA.
Retagliptin phosphate is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor that inhibits DPP-4 to hydrolyze the incretin hormone, thereby increasing the plasma concentration of active glucagon-like peptide-1 (GLP-1) and glucose dependent insulin-like polypeptide (GIP). It increases the release of insulin in a glucose dependent manner and decreases glucagon to reduce blood glucose.
Diabetes is a global disease that poses a serious threat to people’s health and quality of life. According to the International Diabetes Federation (IDF) data (10th edition), the number of adult diabetes patients worldwide has reached 537 million in 2021 and is expected to continue to grow. The number of diabetes patients in China has increased from 90 million in 2011 to 140 million recently, with an increase of 56%.
The treatment of diabetes should consider multiple factors such as blood sugar control, prevention of complications, medication safety, and individual differences of patients. Although existing treatment plans have achieved certain effectiveness, they still face many challenges, especially the occurrence of hypoglycemic events during the treatment of type 2 diabetes, which increases the difficulty of treatment and affects patient survival. The characteristics of individual differences in diabetic patients require personalized treatment plans.
Phase III clinical trail result shows that Retagliptin Phosphate Tablets can significantly reduce HbA1c levels by 1.13% and decrease postprandial blood sugar by 2.69mmol/L in patients with type 2 diabetes. The combination of 50mg BID of Retagliptin Phosphate Tablets and metformin can further reduce HbA1c levels by 1.18% and decrease postprandial blood sugar by 2.71mmol/L in patients with type 2 diabetes. The results indicate that Rigelitinib has a stable therapeutic effect and provides stable blood sugar management for diabetic patients.
As DPP-4 inhibitors,Retagliptin Phosphate Tablets have a unique mechanism of reducing blood sugar levels that can be combined with other anti-diabetic medications to achieve a synergistic effect in lowering blood sugar. When used in combination, DPP-4 inhibitors do not increase the risk of hypoglycemia or gastrointestinal adverse reactions. Additionally, Retagliptin Phosphate Tablets has no induction effect on CYP450 enzymes, and the risk of drug-drug interaction is low, which will promote personalized combination therapy for diabetic patients.
